NV
NVOS.US Novo Integrated Sciences Inc
- Market cap
- USD 15.8K
- P/E
- -
- P/B
- 0.01x
- ROE
- 134.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Nov 2024.
Is NVOS.US undervalued?
Graham numberThe Graham number of Novo Integrated Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novo Integrated Sciences Inc fundamental analysis
No fundamental analysis for Novo Integrated Sciences Inc yet.
Novo Integrated Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novo Integrated Sciences Inc
Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary care and related wellness products and services in Canada. It operates in two segments, Healthcare Services and Product Sales. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesi…
Full company profileNovo Integrated Sciences Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 1 quarter up to Nov 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novo Integrated Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.47M | 7.18M | 7.96M | 8.89M | 9.42M | 7.86M | 9.31M | 11.7M | 12.6M | 13.3M | 12.3M |
| Gross Profit | -335K | 2.51M | 2.98M | 3.42M | 3.52M | 3.06M | 3.82M | 4.80M | 4.95M | 5.74M | 6.31M |
| Operating Income | -573K | 122K | -165K | -1.57M | -786K | -4.26M | -4.27M | -25.0M | -8.55M | -8.31M | -3.75M |
| EBITDA | -87.2K | - | -97.1K | -1.48M | -84.3K | -3.32M | -2.58M | -28.4M | -5.85M | -14.5M | 29.0M |
| Net Income | -1.03M | -341K | -165K | -2.11M | -392K | -4.92M | -4.46M | -33.0M | -13.2M | -16.1M | 20.0M |
| EPS | -6.36 | - | -0.09 | -1.02 | -0.18 | -2.13 | -1.80 | -1.13 | -1.30 | -0.89 | 1.05 |
| Balance Sheet | |||||||||||
| Total Assets | 22.6K | 2.89M | 5.51M | 4.74M | 32.3M | 35.4M | 62.0M | 71.8M | 35.6M | 32.1M | 32.1M |
| Total Liabilities | 648K | 9.97M | 9.80M | 4.57M | 6.73M | 5.82M | 18.2M | 27.4M | 11.1M | 17.5M | 17.5M |
| Shareholders' Equity | -626K | -7.08M | -4.27M | 201K | 25.6M | 29.6M | 43.9M | 44.4M | 24.8M | 14.9M | 14.9M |
| Cash & Short-term Investments | 1.83K | 110K | 1.90M | 676K | 2.08M | 2.07M | 8.29M | 12.7M | 416K | 845K | 845K |
| Total Debt | 523K | - | 5.54M | 1.61M | 5.13M | 4.39M | 13.7M | 19.8M | 4.47M | 4.71M | 4.71M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -145K | 101K | -811K | -935K | -822K | -442K | -1.02M | -5.88M | -2.24M | -2.24M | -2.18M |
| Capital Expenditure | 1.00K | 55.0K | 38.2K | 179K | 108K | 12.1K | 256K | 190K | 49.2K | 49.2K | 12.1K |
| Free Cash Flow | -146K | - | -849K | -1.11M | -930K | -454K | -1.28M | -6.07M | -2.29M | -2.29M | -2.20M |
| Ratios | |||||||||||
| ROE | - | - | - | -1,046.7% | -1.5% | -16.6% | -10.2% | -74.4% | -53.3% | -108.3% | 134.3% |
| ROA | -4,574.8% | -11.8% | -3.0% | -44.4% | -1.2% | -13.9% | -7.2% | -46.0% | -37.2% | -50.2% | 62.2% |
| Net Profit Margin | -13.8% | -4.7% | -2.1% | -23.7% | -4.2% | -62.5% | -48.0% | -281.5% | -105.1% | -121.3% | 162.4% |
| Debt to Equity | - | - | - | 7.98x | 0.20x | 0.15x | 0.31x | 0.45x | 0.18x | 0.32x | 0.32x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novo Integrated Sciences Inc dividends
Novo Integrated Sciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Nov 7, 2023.
Who owns Novo Integrated Sciences Inc
Top funds holding NVOS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Institutional Extnd Mkt Idx Tr | 164K | 0.86% | 0.00% | Sep 2024 |
| Vanguard Total Stock Mkt Idx Inv | 135K | 0.71% | -25.28% | Sep 2024 |
| Fidelity Extended Market Index | 84.3K | 0.44% | -8.34% | Sep 2024 |
| BlackRock Extended Equity Market K | 32.6K | 0.17% | -0.04% | Sep 2024 |
| Fidelity Series Total Market Index | 20.0K | 0.11% | 0.00% | Sep 2024 |
| Fidelity Total Market Index | 18.8K | 0.10% | 0.00% | Sep 2024 |
| NT Ext Equity Mkt Idx Fd - NL | 15.8K | 0.08% | 0.00% | Sep 2024 |
| NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 12.7K | 0.07% | +0.31% | Sep 2024 |
| Northern Trust Extended Eq Market Idx | 12.1K | 0.06% | 0.00% | Sep 2024 |
| NT Ext Equity Mkt Idx Fd - L | 12.1K | 0.06% | 0.00% | Sep 2024 |
| Fidelity Nasdaq Composite Index | 10.1K | 0.05% | 0.00% | Sep 2024 |
| Vanguard U.S. Eq Idx £ Acc | 8.75K | 0.05% | 0.00% | Sep 2024 |
| Spartan Total Market Index Pool E | 7.81K | 0.04% | 0.00% | Sep 2024 |
| Spartan Extended Market Index Pool E | 7.07K | 0.04% | +5.52% | Sep 2024 |
| Extended Equity Market Fund M | 4.14K | 0.02% | -0.24% | Sep 2024 |
| NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 1.87K | 0.01% | +0.16% | Sep 2024 |
| State St US Extended Mkt Indx NL Cl C | 350.00 | 0.00% | 0.00% | Sep 2024 |
| SSgA U.S. Total Market Index Strategy | 144.00 | 0.00% | +42.57% | Jun 2024 |
| State St US Ttl Mkt Indx SL Cl I | 130.00 | 0.00% | 0.00% | Sep 2024 |
| Fidelity U.S. Equity Index Ins Trust | 94.00 | 0.00% | 0.00% | Sep 2024 |
Top institutions holding NVOS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Advisor Group Holdings, Inc. | 0.00 | 0.00% | -100.00% | Mar 2025 |
Novo Integrated Sciences Inc company profile
- Company name
- Novo Integrated Sciences Inc
- Ticker
- NVOS.US
- Exchange
- USA Stocks
- Listed since
- Sep 22, 2017
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 115
- Fiscal year end
- August
- Address
- 11120 NE 2nd Street, Bellevue, WA, United States, 98004
- Phone
- 206 617 9797
- Website
- novointegrated.com
About Novo Integrated Sciences Inc
Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary care and related wellness products and services in Canada. It operates in two segments, Healthcare Services and Product Sales. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women's pelvic health programs, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning programs, including event and game coverage, and private personal training services through clinics. It also provides assessment, diagnosis, treatment, pain management, rehabilitation, education, and prevention of various orthopedic, musculoskeletal, sports injury, and neurological conditions across pediatric, adult, and geriatric populations. In addition, the company offers eldercare physiotherapy services through long-term care homes, retirement homes, community-based home care physiotherapy, community-based group exercise classes and fall prevention programs, and community-based outpatient clinics; and elderly occupational therapy services for retirement homes and community, and long-term care sectors. Further, it provides medical technology platforms, such as Novo Connect, telemedicine/telehealth, and remote patient monitoring; and develops and distributes personalized health and wellness product solutions. The company was formerly known as Turbine Truck Engines, Inc. and changed its name to Nova Integrated Sciences, Inc. in July 2017. The company is headquartered in Bellevue, Washington.
Novo Integrated Sciences Inc management
4- Mr. Robert MattacchioneChairman of the Board & CEO · born 1969
- Mr. Christopher Mehlin DavidCOO & Director · born 1959
- Mr. Vivek Sethi C.A., CPAPrincipal Financial Officer & Principal Accounting Officer · born 1986
- Dr. Joseph M. Chalil FACHE, M.B.A., M.D.Chief Medical Officer